Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Top Cited Papers
- 8 December 2005
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 353 (23), 2462-2476
- https://doi.org/10.1056/nejmoa050516
Abstract
Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor α, is an established treatment for Crohn's disease but not ulcerative colitis.Keywords
This publication has 38 references indexed in Scilit:
- Infliximab for acute, not steroid-refractory ulcerative colitisEuropean Journal of Gastroenterology & Hepatology, 2004
- The Effect of Ageing on Function and Quality of Life in Ileal Pouch PatientsAnnals of Surgery, 2004
- Cytokine-dependent transcriptional down-regulation of epithelial sodium channel in ulcerative colitisGastroenterology, 2004
- Expression of CD45RB functionally distinguishes intestinal T lymphocytes in inflammatory bowel diseaseJournal of Leukocyte Biology, 2004
- Infliximab Maintenance Therapy for Fistulizing Crohn's DiseaseThe New England Journal of Medicine, 2004
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseThe New England Journal of Medicine, 1999
- Comparing functional results one year and ten years after ileal pouch-anal anastomosis for chronic ulcerative colitisDiseases of the Colon & Rectum, 1994
- Construction and initial characterization of a mouse-human chimeric anti-TNF antibodyMolecular Immunology, 1993
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisThe New England Journal of Medicine, 1987